TABLE 3.
Multivariable regression models for pre-HCT and post-HCT disease status
| Overall mortality | Failure for RFS | Relapse | NRM | |
|---|---|---|---|---|
|
| ||||
| Pre-HCT Disease Status | ||||
| MRDneg status (n=216) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| MRDpos status (n=63) | 4.66 (2.95–7.36), P<0.001 | 4.18 (2.73–6.39), P<0.001 | 3.66 (2.19–6.13), P<0.001 | 2.28 (1.00–5.21), P=0.050 |
|
| ||||
| Post-HCT Disease Status | ||||
| MRDneg status (n=263) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| MRDpos status (n=16) | 1.45 (0.72–2.91), P=0.296 | 1.45 (0.72–2.94), P=0.300 | 1.74 (0.73–4.16), P=0.210 | 0.43 (0.04–4.05), P=0.460 |
|
| ||||
| Age | 1.00 (0.98–1.02), P=0.875 | 1.00 (0.98–1.01), P=0.605 | 0.99 (0.97–1.00), P=0.120 | 1.03 (0.99–1.07), P=0.120 |
|
| ||||
| Cytogenetic Risk Group | ||||
| Adverse (n=61) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| Intermediate/favorable (n=212) | 1.15 (0.67–1.97), P=0.617 | 0.93 (0.57–1.53), P=0.774 | 0.76 (0.44–1.32), P=0.330 | 2.27 (0.74–7.00), P=0.150 |
|
| ||||
| Type of AML | ||||
| De novo (n=74) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| Secondary (n=205) | 0.98 (0.62–1.55), P=0.937 | 1.15 (0.76–1.75), P=0.506 | 1.11 (0.70–1.78), P=0.650 | 1.11 (0.43–2.88), P=0.830 |
|
| ||||
| Pre-HCT Karyotype | ||||
| Not normalized (n=39) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| Normalized (n=120) | 0.64 (0.36–1.14), P=0.130 | 0.63 (0.36–1.10), P=0.102 | 0.66 (0.36–1.20), P=0.170 | 0.95 (0.28–3.26), P=0.930 |
|
| ||||
| Pre-HCT Blood Counts* | ||||
| Not recovered (n=55) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| Recovered (n=224) | 1.17 (0.71–1.93), P=0.546 | 1.00 (0.63–1.58), P=0.995 | 0.75 (0.43–1.30), P=0.300 | 1.43 (0.48–4.29), P=0.520 |
*
Recovered: ANC ≥ 1,000/μL and platelets ≥ 100,000/μL; not recovered: ANC <1,000/μL and/or platelets <100,000/μL